IMMATICS NV
Develops cancer immunotherapies designed to target and activate the body’s immune system to recognize and attack cancer cells.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying IMMATICS NV shares due to significant expected price growth.
Financial Health
Immatics NV is showing good revenue and cash flow performance, which indicates strong business activity.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IMTX
Pharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketGerman Stocks Soaring
Discover a carefully selected collection of German companies that have been dramatically outperforming their western counterparts. Our team of professional analysts has identified these standout stocks as Germany's economy shows promising signs of growth in 2025.
Published: May 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline‑driven upside
Immatics’ valuation depends heavily on clinical trial results and regulatory readouts, which can create meaningful movement in either direction; outcomes are uncertain.
TCR technology focus
The company's T‑cell receptor approach targets tumour‑specific antigens that may expand treatment options, though technical and regulatory hurdles remain.
Partnerships and funding
Collaborations and capital support can accelerate development and de‑risk programmes, but clinical‑stage firms commonly require more funding, which can dilute investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
